Immunology

A collection of data (lab analysis and surveys) from a Belgian cohort of healthy people working at five sites across Belgium of the ‘External Department of Prevention and Protection at work’ of Mensura and at Carglass company. Data are about participants' immunity previous and after COVID-19 vaccination (dose 3) using mRNA COVID-19 vaccine BTB162b2. Redu-VAC is a randomised, multicenter, non-inferiority study investigating safety, reactogenicity and immunogenicity of a fractional booster dose (10µg versus 30µg) of the vaccine. Adverse events linked to the vaccination are available.

A collection of data (lab analysis and surveys) from a Belgian cohort of healthy and vulnerable population (elderly people, lung transplant recipients, kidney transplant recipients, immunodialyzed) people. Data are coming from a following of the participants' immunological response to COVID-19 analyzed 3 times a year (February, June, October). Participants' survey with their health status is also available.

A collection of data (lab analysis and surveys) from a Belgian cohort of staff and residents of nursing homes, subsample of the PICOV study. Data are about participants' immunity previous and after COVID-19 vaccination (dose 1 , 2 and 3) using mRNA COVID-19 vaccine BTB162b2. Adverse events linked to the vaccination are available. Participants' survey with their health status is also available.

A collection of data (lab analysis and surveys) from a Belgian cohort of staff and residents of nursing homes from the PICOV study. Data are about participants' immunity previous and after the winter period, on both winter period 2020-2021 and 2021-2022. Respiratory infections were monitored during the 2 winter periods. Participants' survey with their health status is also available.

A collection of data (lab analysis and surveys) from a Belgian cohort of healthy people working at five sites across Belgium of the ‘External Department of Prevention and Protection at work’ of Mensura. Data are about participants' immunity previous and after COVID-19 vaccination (dose 1 and 2) using mRNA COVID-19 vaccine BTB162b2. Redu-VAC is a randomised, multicenter, non-inferiority study investigating safety, reactogenicity and immunogenicity of a fractional dose of the vaccine (20µg versus 30µg). Adverse events linked to the vaccination are available.